Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities researchers at Gabelli issued their FY2017 earnings per share estimates for shares of Zimmer Biomet Holdings in a report released on Thursday. Gabelli analyst J. Tsai expects that the medical equipment provider will earn $8.25 per share for the year. Gabelli currently has a “Buy” rating and a $142.00 target price on the stock. Gabelli also issued estimates for Zimmer Biomet Holdings’ FY2018 earnings at $8.90 EPS and FY2021 earnings at $11.70 EPS.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. During the same quarter in the prior year, the business posted $2.02 EPS. Zimmer Biomet Holdings’s revenue was up 1.1% compared to the same quarter last year.

ILLEGAL ACTIVITY NOTICE: “Gabelli Comments on Zimmer Biomet Holdings, Inc.’s FY2017 Earnings (ZBH)” was reported by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/08/28/gabelli-comments-on-zimmer-biomet-holdings-inc-s-fy2017-earnings-zbh.html.

ZBH has been the subject of a number of other reports. Stifel Nicolaus reiterated a “hold” rating and issued a $125.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 8th. BMO Capital Markets reiterated a “buy” rating and issued a $136.00 price objective on shares of Zimmer Biomet Holdings in a research note on Tuesday, July 11th. Wells Fargo & Company reiterated a “market weight” rating on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $148.00 price objective on shares of Zimmer Biomet Holdings in a research note on Friday, June 30th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Zimmer Biomet Holdings presently has an average rating of “Hold” and an average target price of $136.75.

Shares of Zimmer Biomet Holdings (ZBH) opened at 113.19 on Monday. The company has a market cap of $22.89 billion, a P/E ratio of 32.24 and a beta of 1.20. The firm has a 50 day moving average price of $120.75 and a 200-day moving average price of $120.97. Zimmer Biomet Holdings has a 12 month low of $95.63 and a 12 month high of $133.49.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.85%. The ex-dividend date of this dividend is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio is presently 27.59%.

In other Zimmer Biomet Holdings news, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The disclosure for this sale can be found here. Insiders own 1.07% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the company. Bronfman E.L. Rothschild L.P. increased its stake in Zimmer Biomet Holdings by 25.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 167 shares in the last quarter. Parkside Financial Bank & Trust increased its stake in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares in the last quarter. BB&T Investment Services Inc. acquired a new stake in Zimmer Biomet Holdings during the second quarter valued at $144,000. Parallel Advisors LLC increased its stake in Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares in the last quarter. Finally, IHT Wealth Management LLC increased its stake in Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares in the last quarter. 82.84% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Earnings History and Estimates for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.